A study from the University of Pennsylvania, presented at the 2024 Digestive Disease Week (DDW), found that GLP-1 receptor agonists are effective for weight loss in patients with inflammatory bowel disease (IBD) and are well-tolerated, showing a similar safety profile to that seen in the general population. Conducted by Dr. Priya Sehgal and colleagues, this study evaluated 244 patients with Crohn’s disease and ulcerative colitis on GLP-1 therapy for three to six months, noting an average weight reduction of just over 5% at 12 weeks. Semaglutide users experienced slightly higher weight loss, with reductions exceeding 6%.
Study Finds GLP-1s Safe and Effective For Managing Obesity in Patients With IBD (GI & Endoscopy News)
0